TB-500, Thymosin Beta-4
Identity hold Research draft Repair and healing research No graded treatment evidence Identity hold: product contents not confirmed
Evidence design, not proof of benefit or product approval
Holds on this record
- Identity hold. The exact contents or formulation are not confirmed. It cannot be placed in an active plan.
- No supplier batch has been matched to this record. A reviewer must record batch evidence before approval.
- Not marked ready for client selection in the library.
- No human administration guide. Study routes are research descriptions, not instructions.
- Research draft. Not released customer guidance.
The nine headings
Each heading opens a plain summary, then the deeper evidence and the sources behind it.
What it is
The catalog joins TB-500 and thymosin beta-4. They must be separated before evidence is assigned.
Sources for this tile
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)
The history
FDA identifies a thymosin beta-4 fragment called LKKTETQ in its compounding notice. A fragment is only part of a larger peptide.
Sources for this tile
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)
How it works
No specific mechanism claim is cleared in this first record. A pathway, if later verified, still needs human outcomes before it can support a benefit claim.
What it helps
This product has an identity hold. Benefits cannot be assigned until the exact compound or formula is known.
Read this before you read a benefit into it
Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.
No human study is recorded for this product in this edition.
The research
Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.
Sources for this tile
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)
Overall state of the evidence
Status: identity-hold
Hold identity. Confirm whether the product is full-length thymosin beta-4, the named fragment, or another sequence. Full-length research cannot prove fragment effects.
Risk summary
Hold identity. Confirm whether the product is full-length thymosin beta-4, the named fragment, or another sequence. Full-length research cannot prove fragment effects.
What is still open
- Supplier identity and batch match have not been verified
- Full-text systematic review and complete interactions are not finished
- Full amino acid sequence
- Fragment or full-length identity
- Route-specific studies
Checks a reviewer must finish first
- Full amino acid sequence
- Fragment or full-length identity
- Route-specific studies
How to read the proof grades
- A: Controlled human trial. Note whether randomisation and blinding were confirmed.
- B: Small uncontrolled human study or chart review.
- C: Whole-animal intervention.
- D: Cell or other laboratory study.
- E: User reports. Kept separate and never substituted for a measured outcome.
- ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.
Go deeper
How to read the proof Open the checked detail
A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.
A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.
Sources
- Future Health research method (Christopher’s supplied research method; read in full · checked 2026-10-09)
Open questions Open the checked detail
Supplier identity and batch match have not been verified
Full-text systematic review and complete interactions are not finished
Full amino acid sequence
Fragment or full-length identity
Route-specific studies
Research in people
No qualifying product-matched human treatment result was verified in this pass. This is a search limit, not a claim that no study exists.
What people report
No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.
No human study record is attached to this product in this edition.
Why it is for you
This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
What you would notice
Hold identity. Confirm whether the product is full-length thymosin beta-4, the named fragment, or another sequence. Full-length research cannot prove fragment effects.
Sources for this tile
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)
Not filled in for you yet
This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.
How it is taken
No route is assigned until the exact compound is known. Research routes describe what was studied. They are not a client administration guide.
Sources for this tile
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)
Routes seen in the research
No human route is recorded.
Dose and cycle fields in the library
These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.
| dose | Blank |
|---|---|
| unit | Blank |
| frequency | Blank |
| timeOfDay | Blank |
| foodTiming | Blank |
| route | Blank |
| injectionSite | Blank |
| cycleLength | Blank |
| restLength | Blank |
| titration | Blank |
| mixing | Blank |
| storage | Blank |
| expiryAfterMixing | Blank |
Identity
| What it is made of | The catalog joins TB-500 and thymosin beta-4. They must be separated before evidence is assigned. |
|---|---|
| Maker | Not recorded |
| Supplier batch matched | No. Not matched to a supplier batch. |
| Catalog sizes | 5mg to 10mg - Inherited reference only; stock and current product sizes unverified |
| Record checked on | 2026-10-08 |
Shared safety note
FDA flags immune reactions and impurities in several compounded peptides. Its notice also reports serious events in IV ipamorelin research, heart-rate and vessel-dilation reactions with CJC-1295, glucose concerns with GHRP-2/6, and serious case reports with melanotan II. Reports do not by themselves establish causation. This concerns proposed compounded products and routes, not every formulation worldwide.
Source
- FDA: compounding safety concerns (FDA · Official safety notice · checked 2026-10-08)